These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1286 related articles for article (PubMed ID: 31443960)

  • 21. Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK.
    Grabe-Heyne K; Henne C; Odeyemi I; Pöhlmann J; Ahmed W; Pollock RF
    J Med Econ; 2023; 26(1):411-421. PubMed ID: 36897006
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intermediate-risk Non-muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group.
    Tan WS; Steinberg G; Witjes JA; Li R; Shariat SF; Roupret M; Babjuk M; Bivalacqua TJ; Psutka SP; Williams SB; Cookson MS; Palou J; Kamat AM
    Eur Urol Oncol; 2022 Oct; 5(5):505-516. PubMed ID: 35718695
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer.
    Monteiro LL; Witjes JA; Agarwal PK; Anderson CB; Bivalacqua TJ; Bochner BH; Boormans JL; Chang SS; Domínguez-Escrig JL; McKiernan JM; Dinney C; Godoy G; Kulkarni GS; Mariappan P; O'Donnell MA; Rentsch CA; Shah JB; Solsona E; Svatek RS; van der Heijden AG; van Valenberg FJP; Kassouf W
    World J Urol; 2019 Jan; 37(1):51-60. PubMed ID: 30109483
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations: prospective randomised FinnBladder-4 study.
    Järvinen R; Marttila T; Kaasinen E; Rintala E; Aaltomaa S; Kallio J; Liukkonen T; Puolakka VM; Seppänen M; Tuhkanen K; Vaarala M; Viitanen J; Boström PJ;
    Eur Urol; 2015 Oct; 68(4):611-7. PubMed ID: 25748117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Validation of EORTC, CUETO, and EAU risk stratification in prediction of recurrence, progression, and death of patients with initially non-muscle-invasive bladder cancer (NMIBC): A cohort analysis.
    Jobczyk M; Stawiski K; Fendler W; Różański W
    Cancer Med; 2020 Jun; 9(11):4014-4025. PubMed ID: 32216043
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of High-grade Non-muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial "NIMBUS".
    Grimm MO; van der Heijden AG; Colombel M; Muilwijk T; Martínez-Piñeiro L; Babjuk MM; Türkeri LN; Palou J; Patel A; Bjartell AS; Caris C; Schipper RG; Witjes WPJ;
    Eur Urol; 2020 Nov; 78(5):690-698. PubMed ID: 32446864
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation?
    Sylvester RJ; Oosterlinck W; Holmang S; Sydes MR; Birtle A; Gudjonsson S; De Nunzio C; Okamura K; Kaasinen E; Solsona E; Ali-El-Dein B; Tatar CA; Inman BA; N'Dow J; Oddens JR; Babjuk M
    Eur Urol; 2016 Feb; 69(2):231-44. PubMed ID: 26091833
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognosis of Primary Papillary Ta Grade 3 Bladder Cancer in the Non-muscle-invasive Spectrum.
    Beijert IJ; Hentschel AE; Bründl J; Compérat EM; Plass K; Rodríguez O; Subiela Henríquez JD; Hernández V; de la Peña E; Alemany I; Turturica D; Pisano F; Soria F; Čapoun O; Bauerová L; Pešl M; Bruins HM; Runneboom W; Herdegen S; Breyer J; Brisuda A; Calatrava A; Rubio-Briones J; Seles M; Mannweiler S; Bosschieter J; Kusuma VRM; Ashabere D; Huebner N; Cotte J; Mertens LS; Claps F; Masson-Lecomte A; Liedberg F; Cohen D; Lunelli L; Cussenot O; El Sheikh S; Volanis D; Côté JF; Rouprêt M; Haitel A; Shariat SF; Mostafid AH; Nieuwenhuijzen JA; Zigeuner R; Dominguez-Escrig JL; Hacek J; Zlotta AR; Burger M; Evert M; Hulsbergen-van de Kaa CA; van der Heijden AG; Kiemeney LALM; Soukup V; Molinaro L; Gontero P; Llorente C; Algaba F; Palou J; N'Dow J; Ribal MJ; van der Kwast TH; Babjuk M; Sylvester RJ; van Rhijn BWG
    Eur Urol Oncol; 2023 Apr; 6(2):214-221. PubMed ID: 36670042
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [A Randomized Controlled Study of Intravesical Instillation Therapy of Bacillus Calmette-Guérin vs. Epirubicinin Treating Non-muscular Invasive Bladder Cancer].
    Yang WX; Shao YX; Hu X; Xiong SC; Liu Y; Li X
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2021 Mar; 52(2):326-333. PubMed ID: 33829710
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma.
    Miyake M; Tatsumi Y; Matsumoto H; Nagao K; Matsuyama H; Inamoto T; Azuma H; Yasumoto H; Shiina H; Fujimoto K;
    BJU Int; 2018 May; 121(5):764-773. PubMed ID: 29281857
    [TBL] [Abstract][Full Text] [Related]  

  • 31. International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin-exposed High-risk Non-muscle-invasive Bladder Cancer.
    Roumiguié M; Kamat AM; Bivalacqua TJ; Lerner SP; Kassouf W; Böhle A; Brausi M; Buckley R; Persad R; Colombel M; Lamm D; Palou-Redorta J; Soloway M; Brothers K; Steinberg G; Lotan Y; Sylvester R; Alfred Witjes J; Black PC
    Eur Urol; 2022 Jul; 82(1):34-46. PubMed ID: 34955291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer.
    Alfred Witjes J; Lebret T; Compérat EM; Cowan NC; De Santis M; Bruins HM; Hernández V; Espinós EL; Dunn J; Rouanne M; Neuzillet Y; Veskimäe E; van der Heijden AG; Gakis G; Ribal MJ
    Eur Urol; 2017 Mar; 71(3):462-475. PubMed ID: 27375033
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Electromotive Drug Administration of Mitomycin C (EMDA/MMC) versus Intravesical Immunotherapy with Bacillus Calmette-Guérin (BCG) in Intermediate and High Risk Non Muscle Invasive Bladder Cancer.
    Zazzara M; Nazaraj A; Scarcia M; Cardo G; Carando R; Ludovico GM
    Urol Int; 2023; 107(1):64-71. PubMed ID: 34933307
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
    Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
    Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin.
    Li R; Sundi D; Zhang J; Kim Y; Sylvester RJ; Spiess PE; Poch MA; Sexton WJ; Black PC; McKiernan JM; Steinberg GD; Kamat AM; Gilbert SM
    Eur Urol; 2020 Sep; 78(3):387-399. PubMed ID: 32143924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low compliance to guidelines in nonmuscle-invasive bladder carcinoma: A systematic review.
    Mori K; Miura N; Babjuk M; Karakiewicz PI; Mostafaei H; Laukhtina E; Quhal F; Motlagh RS; Pradere B; Kimura S; Egawa S; Shariat SF
    Urol Oncol; 2020 Oct; 38(10):774-782. PubMed ID: 32654948
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selection of adjuvant intravesical therapies using the European Organization for Research and Treatment of Cancer scoring system in patients at intermediate risk of non-muscle-invasive bladder cancer.
    Ofude M; Kitagawa Y; Yaegashi H; Izumi K; Ueno S; Kadono Y; Konaka H; Mizokami A; Namiki M
    J Cancer Res Clin Oncol; 2015 Jan; 141(1):161-8. PubMed ID: 25108407
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment and surveillance for non-muscle-invasive bladder cancer: a clinical practice guideline (2021 edition).
    Jin YH; Zeng XT; Liu TZ; Bai ZM; Dou ZL; Ding DG; Fan ZL; Han P; Huang YR; Huang X; Li M; Li XD; Li YN; Li XH; Liang CZ; Liu JM; Ma HS; Qi J; Shi JQ; Wang J; Wang DL; Wang ZP; Wang YY; Wang YB; Wei Q; Xia HB; Xing JC; Yan SY; Zhang XP; Zheng GY; Xing NZ; He DL; Wang XH;
    Mil Med Res; 2022 Aug; 9(1):44. PubMed ID: 35978389
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.
    Shelley MD; Jones G; Cleves A; Wilt TJ; Mason MD; Kynaston HG
    BJU Int; 2012 Feb; 109(4):496-505. PubMed ID: 22313502
    [TBL] [Abstract][Full Text] [Related]  

  • 40. French AFU Cancer Committee Guidelines - Update 2022-2024: Non-muscle-invasive bladder cancer (NMIBC).
    Neuzillet Y; Pradère B; Xylinas E; Allory Y; Audenet F; Loriot Y; Masson-Lecomte A; Roumiguié M; Seisen T; Traxer O; Leon P; Roupret M
    Prog Urol; 2022 Nov; 32(15):1102-1140. PubMed ID: 36400479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 65.